BioSyent to Acquire Oral Science Inc.

Core Viewpoint - BioSyent Inc. has announced the acquisition of Oral Science Inc., a Canadian distributor of dental healthcare products, for a total purchase price of $25.5 million, which includes cash and shares, aiming to enhance its revenue and diversify its product portfolio [1][2][11]. Transaction Details - The acquisition involves BioSyent purchasing 100% of Oral Science's shares for $25.5 million, comprising $22.5 million in cash and $3.0 million in BioSyent common shares [2]. - The transaction is expected to close by the end of February 2026, pending customary closing conditions and regulatory approvals [3]. About Oral Science - Oral Science, founded in 2003, specializes in dental products and has a diversified sales model, generating over $30 million in gross revenues and more than $4 million in EBITDA for the trailing twelve months ending September 30, 2025 [4][5]. - Approximately one-third of Oral Science's sales come from proprietary products, while two-thirds are from exclusive distribution agreements [4]. Strategic Fit with BioSyent - The acquisition aligns with BioSyent's business model, enhancing its distribution channels and relationships with dental health professionals [6][8]. - Oral Science generates 54% of its revenue from dental clinics and 46% from consumer purchases, providing a balanced sales approach [7]. Future Operations - Oral Science will operate as a standalone business unit within BioSyent, with its current leadership continuing to manage the company [9]. - BioSyent plans to invest in new pharmaceutical and oral health products to drive growth for both companies [9]. Transaction Financing - The acquisition will be financed through BioSyent's liquid cash and a $6.0 million term loan, with expectations to maintain a strong net cash position post-transaction [10]. Key Transaction Highlights - The acquisition is projected to be accretive, with combined pro forma revenues exceeding $70 million and pro forma EBITDA over $15.75 million for the trailing twelve months ending September 30, 2025 [11][12]. - The purchase price implies a multiple of 6.33 times EBITDA, indicating an attractive rate of return for BioSyent [12]. Strategic Priorities - This acquisition supports BioSyent's goals of profitable growth, diversification, and long-term value creation, enhancing its commercial organization [13][14].